Dr. Reddy's Laboratories shares are trading lower after the company reported worse-than-expected Q1 financial results. Also, President Trump announced a 100% import tariffs on imported generic drugs after a two-year grace period.

Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth

The global substance use disorder treatment market is projected to grow from $11.6 billion in 2025 to $14.6 billion by 2030, with a compound annual growth rate of 4.6%. Growth is driven by long-acting therapies, telemedicine expansion, drug innovation, and increased government interventions, though challenges include low treatment penetration and stigma.

Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450

Dr. Reddy's Expands Collaboration With Gilead Sciences Through Voluntary Licensing Agreement For Investigational Once-Yearly Lenacapavir For HIV Prevention

Dr Reddy's Laboratories Q1 2027 Earnings Call Transcript

Dr Reddy's Laboratories (NYSE:RDY) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial